Traci N Bethea1,2, Julie R Palmer3, Lucile L Adams-Campbell4, Lynn Rosenberg3. 1. Slone Epidemiology Center, Boston University, 1010 Commonwealth Avenue, Boston, MA, 02215, USA. tnb@bu.edu. 2. Department of Medicine, Boston University School of Medicine, 715 Albany St. E-113, Boston, MA, 02118, USA. tnb@bu.edu. 3. Slone Epidemiology Center, Boston University, 1010 Commonwealth Avenue, Boston, MA, 02215, USA. 4. Division of Cancer Prevention and Control, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, 1000 New Jersey Ave SE, Washington, DC, 20003, USA.
Abstract
PURPOSE: Extensive data in White women have linked oral contraceptive use, tubal ligation, and parity to reduced risk of ovarian cancer; results on postmenopausal female hormone use are mixed. Few studies, all of which are case-control studies, have been undertaken among Black women. The aim of the present study was to prospectively assess associations of reproductive factors and exogenous hormones with ovarian cancer among Black women. METHODS: During follow-up from 1995 to 2013 in the Black Women's Health Study, a prospective cohort study, 115 incident cases of ovarian cancer were identified. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the relation of the factors of interest to risk of ovarian cancer, with control for covariates. RESULT: Oral contraceptive use was inversely associated with ovarian cancer risk: The HR for ≥10 years of use relative to <1 year was 0.50 (95% CI 0.30-0.98). For postmenopausal female hormone use, the HRs for ever use of estrogen with progestin and of estrogen alone were 1.37 (0.73-2.55) and 1.66 (0.90-3.07), respectively. The HRs for parity and tubal ligation were below 1.0, but were not statistically significant. CONCLUSION: Overall, the findings indicate that the relation of reproductive factors and exogenous hormone use to risk of ovarian cancer is similar among Black and White women. The results on estrogen-only supplements and estrogen with progestin supplements add to evidence from Whites, indicating that use of hormone supplements may be associated with increased risk of ovarian cancer.
PURPOSE: Extensive data in White women have linked oral contraceptive use, tubal ligation, and parity to reduced risk of ovarian cancer; results on postmenopausal female hormone use are mixed. Few studies, all of which are case-control studies, have been undertaken among Black women. The aim of the present study was to prospectively assess associations of reproductive factors and exogenous hormones with ovarian cancer among Black women. METHODS: During follow-up from 1995 to 2013 in the Black Women's Health Study, a prospective cohort study, 115 incident cases of ovarian cancer were identified. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the relation of the factors of interest to risk of ovarian cancer, with control for covariates. RESULT: Oral contraceptive use was inversely associated with ovarian cancer risk: The HR for ≥10 years of use relative to <1 year was 0.50 (95% CI 0.30-0.98). For postmenopausal female hormone use, the HRs for ever use of estrogen with progestin and of estrogen alone were 1.37 (0.73-2.55) and 1.66 (0.90-3.07), respectively. The HRs for parity and tubal ligation were below 1.0, but were not statistically significant. CONCLUSION: Overall, the findings indicate that the relation of reproductive factors and exogenous hormone use to risk of ovarian cancer is similar among Black and White women. The results on estrogen-only supplements and estrogen with progestin supplements add to evidence from Whites, indicating that use of hormone supplements may be associated with increased risk of ovarian cancer.
Entities:
Keywords:
African-American; Ovarian cancer; Reproductive factors; Women
Authors: Megan S Rice; Megan A Murphy; Allison F Vitonis; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry Journal: Int J Cancer Date: 2013-07-09 Impact factor: 7.396
Authors: Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore Journal: Int J Epidemiol Date: 2013-04 Impact factor: 7.196
Authors: Joellen M Schildkraut; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michelle L Cote; Ellen Funkhouser; Edward Peters; Ann G Schwartz; Paul Terry; Kristin Wallace; Lucy Akushevich; Frances Wang; Sydnee Crankshaw; Patricia G Moorman Journal: BMC Cancer Date: 2014-09-22 Impact factor: 4.430
Authors: Joellen M Schildkraut; Lauren C Peres; Traci N Bethea; Fabian Camacho; Deanna Chyn; Emily K Cloyd; Elisa V Bandera; Alicia Beeghly-Fadiel; Loren Lipworth; Charlotte E Joslin; Faith G Davis; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Veronica Wendy Setiawan; Malcolm C Pike; Anna H Wu; Lynn Rosenberg Journal: Cancer Causes Control Date: 2019-06-24 Impact factor: 2.506
Authors: Heather M Ochs-Balcom; Courtney Johnson; Kristin A Guertin; Bo Qin; Alicia Beeghly-Fadiel; Fabian Camacho; Traci N Bethea; Lauren F Dempsey; Will Rosenow; Charlotte E Joslin; Evan Myers; Patricia G Moorman; Holly R Harris; Lauren C Peres; V Wendy Setiawan; Anna H Wu; Lynn Rosenberg; Joellen M Schildkraut; Elisa V Bandera Journal: Br J Cancer Date: 2022-09-22 Impact factor: 9.075
Authors: Holly R Harris; Kristin A Guertin; Tareq F Camacho; Courtney E Johnson; Anna H Wu; Patricia G Moorman; Evan Myers; Traci N Bethea; Elisa V Bandera; Charlotte E Joslin; Heather M Ochs-Balcom; Lauren C Peres; Will T Rosenow; Veronica W Setiawan; Alicia Beeghly-Fadiel; Lauren F Dempsey; Lynn Rosenberg; Joellen M Schildkraut Journal: Int J Cancer Date: 2022-06-30 Impact factor: 7.316
Authors: Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Lauren C Peres; Traci N Bethea; Tareq F Camacho; Elisa V Bandera; Alicia Beeghly-Fadiel; Deanna L Chyn; Holly R Harris; Charlotte E Joslin; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Will Rosenow; V Wendy Setiawan; Anna H Wu; Lynn Rosenberg; Joellen M Schildkraut Journal: J Natl Cancer Inst Date: 2021-06-01 Impact factor: 13.506
Authors: Yang Liu; Lan Ma; Xiaoling Yang; Jia Bie; Dongya Li; Chunyi Sun; Jie Zhang; Yushi Meng; Jie Lin Journal: Front Endocrinol (Lausanne) Date: 2019-12-03 Impact factor: 5.555